An evidence-based overview of the Cuban medical innovations offered through our treatment programs, with links to authoritative sources.
Cuba has a decades-long tradition of biotechnology and medical research, anchored by institutions such as the Center for Genetic Engineering and Biotechnology (CIGB) and the Center of Molecular Immunology (CIM). Several therapies developed in Cuba are now studied internationally. This page provides factual, referenced context — not medical advice.
A recombinant human epidermal growth factor (EGF) administered by intralesional injection to promote wound healing in advanced diabetic foot ulcers, developed by Cuba's Center for Genetic Engineering and Biotechnology (CIGB).
A therapeutic vaccine targeting epidermal growth factor (EGF), developed by Cuba's Center of Molecular Immunology (CIM), studied as a maintenance therapy in non-small cell lung cancer.
An anti-idiotypic vaccine inducing an immune response against N-ganglioside NeuGcGM3, investigated as immunotherapy for advanced non-small cell lung cancer.
A brain tissue-derived therapy used in Cuba as part of comprehensive neurological rehabilitation programs for conditions including stroke and neurodegenerative disease.
Cuba's integrated dermatological protocol for vitiligo, combining topical therapies, phototherapy, and clinical follow-up, widely sought by international patients.
We encourage patients and their home physicians to consult primary sources. The following are authoritative, independent databases where peer-reviewed studies on these therapies can be found:
Some therapies available in Cuba may not yet be approved or available in your country of residence. Availability and eligibility for any treatment are determined on an individual clinical basis. This page is for educational purposes and is not a substitute for professional medical advice.
Learn how these innovations are applied within our clinical programs, or read expert-reviewed condition guides in our Medical Knowledge Hub.